KR900018369A - Method of Purifying Human Gonadotropin - Google Patents

Method of Purifying Human Gonadotropin Download PDF

Info

Publication number
KR900018369A
KR900018369A KR1019890007464A KR890007464A KR900018369A KR 900018369 A KR900018369 A KR 900018369A KR 1019890007464 A KR1019890007464 A KR 1019890007464A KR 890007464 A KR890007464 A KR 890007464A KR 900018369 A KR900018369 A KR 900018369A
Authority
KR
South Korea
Prior art keywords
hcg
ionic strength
urine
buffer
column
Prior art date
Application number
KR1019890007464A
Other languages
Korean (ko)
Other versions
KR960012216B1 (en
Inventor
최우성
한열수
신기락
Original Assignee
안시환
제일제당 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 안시환, 제일제당 주식회사 filed Critical 안시환
Priority to KR1019890007464A priority Critical patent/KR960012216B1/en
Publication of KR900018369A publication Critical patent/KR900018369A/en
Application granted granted Critical
Publication of KR960012216B1 publication Critical patent/KR960012216B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

내용 없음No content

Description

사람의 응모성 성선 호르몬의 정제 방법Method of Purifying Human Gonadotropin

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

제1도는 이온 강도를 조절하지 않은 경우, 비특이적인 물질이 컬럼에서 쉽게 세척되지 않아 용출이 완전하게 되지 않음을 보여주는 그래프이고, 제2도는 이온 강도를 보통 수준으로 높였을 경우와 조절하지 않았을 경우의 전기영동 결과이며, 제3도는 이온 강도를 조절한 경우, 컬럼 세척 및 용출의 모양.FIG. 1 is a graph showing that elution is not complete because nonspecific materials are not easily washed off the column when the ionic strength is not adjusted. FIG. 2 shows the case where the ionic strength is increased to the normal level and not adjusted. Results of electrophoresis, FIG. 3 shows the shape of column washes and elution when ionic strength is controlled.

Claims (7)

hCG에 특이성을 갖는 단일 클론 항체를 고체상 매트릭스에 결합시킨 컬럼을 사용함을 특징으로 하는 응모성 성선 호르몬의 정제 방법.A method for purifying enter gonadotropin comprising using a column in which a monoclonal antibody having specificity for hCG is bound to a solid phase matrix. 제1항에 있어서, 항체는 온전한 hCG에 높은 친화력을 갖고 b사슬에는 약간의 친화력을 갖는 것임을 특징으로 하는 방법.The method of claim 1, wherein the antibody has a high affinity for intact hCG and a slight affinity for the b chain. 제1항에 있어서, 뇨에 μ=0.2-0.5의 이온 강도를 갖게하여 고순도의 hCG를 분리함을 특징으로 하는 방법.The method of claim 1, wherein the urine has an ionic strength of μ = 0.2-0.5 to separate high purity hCG. 제1항에 있어서, 뇨에 μ=0.02-01의 이온 강도를 갖게하여 hCG의 b사슬을 포함하게 함을 특징으로 하는 방법.The method of claim 1, wherein the urine has an ionic strength of μ = 0.02-01 to include the b chain of hCG. 제1항 및 제4항에 있어서, 컬럼에서 hCG를 용출시킬 때 이온 강도 v=0.5-1.0인 완충액(pH3.0)을 사용함을 특징으로 하는 방법.The method according to claim 1 or 4, characterized in that a buffer (pH 3.0) with ionic strength v = 0.5-1.0 is used when eluting hCG in the column. 제3항 및 제4항에 있어서, 뇨의 이온 강도는 인산염 완충액 혹은 염화 나트륨을 사용하여 조절함을 특징으로 하는 방법.5. The method of claim 3 and 4, wherein the ionic strength of urine is controlled using phosphate buffer or sodium chloride. 제5항에 있어서, 완충액은 20-100mM 구연산-인산 완충액임을 특징으로 하는 방법.The method of claim 5, wherein the buffer is 20-100 mM citric acid-phosphate buffer. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019890007464A 1989-05-31 1989-05-31 Purification process of human chorionic gonadotropin KR960012216B1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1019890007464A KR960012216B1 (en) 1989-05-31 1989-05-31 Purification process of human chorionic gonadotropin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019890007464A KR960012216B1 (en) 1989-05-31 1989-05-31 Purification process of human chorionic gonadotropin

Publications (2)

Publication Number Publication Date
KR900018369A true KR900018369A (en) 1990-12-21
KR960012216B1 KR960012216B1 (en) 1996-09-16

Family

ID=19286699

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890007464A KR960012216B1 (en) 1989-05-31 1989-05-31 Purification process of human chorionic gonadotropin

Country Status (1)

Country Link
KR (1) KR960012216B1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100701396B1 (en) * 2000-08-28 2007-03-28 주식회사유한양행 A process for the purification of human chorionic gonadotrophin

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100701396B1 (en) * 2000-08-28 2007-03-28 주식회사유한양행 A process for the purification of human chorionic gonadotrophin

Also Published As

Publication number Publication date
KR960012216B1 (en) 1996-09-16

Similar Documents

Publication Publication Date Title
ES2181674T3 (en) UNION DOMAINS IN THE PROTEINS NOTCH AND DELTA.
HK1025977A1 (en) Oil bodies and associated proteins as affinity matrices
DE69434520D1 (en) BIOTINYLATION OF PROTEINS
DE69008423T2 (en) Dynamic fixation of porcine acid valves.
MX9702388A (en) Monoclonal antibody to human cardiac myoglobin.
FI864427A (en) A method of making a polypeptide that is complementary to at least a portion of the parent peptide or protein, and the use of the complementary polypeptide
NO976122L (en) Anti-Phase ligand antibodies and assay method where used
DE69021953T2 (en) Enzyme immunoassay for antigens and solid phase that can be used for them.
DK37590A (en) METHOD OF INVESTIGATION FOR 1,25-DIHYDROXY VITAMIN D
FR2560212B1 (en) MONOCLONAL ANTIBODIES AGAINST INTERFERON A2 AND HYBRIDOMAS PRODUCING SUCH ANTIBODIES
KR900018369A (en) Method of Purifying Human Gonadotropin
Subramanian et al. Characterization of a mutant form of ribosomal protein S1 from Escherichia coli.
DE69001039D1 (en) NON-ALKALINE SWEETING OF HYDROCARBON FRACTIONS.
GB9507985D0 (en) Antibody to aminoterminal propeptide to type 1 procollagen and assay method using it
KR910003092A (en) HCG Peptides for Use in Antibody Purification Methods
KR910005885A (en) Activation of Protein C
FR2709492B1 (en) Immunoassay specific for human plasma glutathione peroxidase, kit for its implementation, oligopeptides and antibodies specific for the method.
EP0608117A3 (en) Antibodies for mevalonic acid and methods for determination of mevalonic acid.
DK0535347T3 (en)
WO1999024835A3 (en) An immunoassay for procollagen-iii-c-terminal propeptide
DE3780446T2 (en) METHOD FOR DETERMINING PREGNANCY INTERVENTIONS.
ES8606500A1 (en) Process for determining the presence of a specific IgE in human sera
AU653182B2 (en) Process for selective removal of salivary alpha-amylase and assay for pancreatic alpha-amylase
ATE83930T1 (en) ANTIBODY CONTAINING STABILIZED AQUEOUS COMPOSITION.
FI893333A0 (en) Method and reagent for the determination of antibodies

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20020715

Year of fee payment: 7

LAPS Lapse due to unpaid annual fee